|Composition of Product||Meropenem 250 mg|
|Pack Size||250 mg|
|Pack Type||Vial with SWFI|
|Storage||store in a cool place|
Meropenem 250mg Salt Information :
Side Effects of Meropenem 250mg:
Diarrhoea, nausea, vomiting, abdominal pain; headache; constipation; rash, pruritus, uticaria; apnoea; phlebitis, thrombophlebitis, swelling and pain at inj site; disturbances in LFTs (may cause increases in serum transaminases, alkaline phosphatase, lactic dehydrogenase). Rarely: erythema multiforme; eosinophilia, thrombocytopenia, leucopenia, neutropenia; seizures and CNS effects reported in patients with underlying CNS disorders or renal impairment. Potentially Fatal: Anaphylaxis; pseudomembranous colitis; Stevens-Johnsons sydrome.
Drug Interactions of Meropenem 250mg:
Serum levels may be increased by probenecid. May reduce serum valproic acid levels; sub-therapeutic levels may be reached in some patients.
Contraindications of Meropenem 250mg:
Mechanism of Action of Meropenem 250mg:
Meropenem is a carbapenem that works by inhibiting the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting to bacterial lysis. Distribution: Widely distributed into body tissues and fluids; CSF; bile. Metabolism: More stable to renal dehydropeptidases; converted to one inactive metabolite. Excretion: Via urine within 12 hr by glomerular filtration and tubular secretion (70% unchanged). Elimination half-life: 1 hr. Removed by dialysis.
Special Precautions for Meropenem 250mg:
History of hypersensitivity to carbapenem, pencillins or other β-lactam antibiotics; infants <3 mth; renal insufficiency; neurological disorders; pregnancy, lactation. Not recommended for use in MRSA.